Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a $30 price target.
August 07, 2024 | 5:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Olema Pharmaceuticals and maintained a $30 price target.
The reiteration of an Outperform rating and the maintenance of a $30 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100